CDC/ACIP [to 23 July 2016]

CDC/ACIP [to 23 July 2016]

Press Release
CDC awards $60 million to help states and territories battle Zika
The Centers for Disease Control and Prevention (CDC) will begin making awards totaling nearly $60 million to states, cities, and territories to support efforts to protect Americans from Zika virus…

Media Advisory
Webcast: Clinical Evaluation & Management of Infants with Congenital Zika Infection
CDC will host a meeting in collaboration with the American Academy of Pediatrics.

TUESDAY, JULY 19, 2016
Transcript for CDC Media Availability: Support for Utah investigation of Zika

Media Statement
MONDAY, JULY 18, 2016
CDC assisting Utah investigation of Zika virus infection apparently not linked to travel
CDC is assisting in the investigation of a case of Zika in a Utah resident who is a family contact of the elderly Utah resident who died in late June….


MMWR Weekly July 22, 2016, 65/No. 28
:: World Hepatitis Day — July 28, 2016
:: Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission — United States and Kentucky, 2011–2014
:: Projected Zika Virus Importation and Subsequent Ongoing Transmission after Travel to the 2016 Olympic and Paralympic Games — Country-Specific Assessment, July 2016
:: Suspected Female-to-Male Sexual Transmission of Zika Virus — New York City, 2016

IFRC [to 23 July 2016]

IFRC [to 23 July 2016]

22 July 2016
Democratic Republic of the Congo: Red Cross launches emergency appeal to fight multiple deadly disease outbreaks
Yaoundé, Geneva – 22 July 2016 – In light of several epidemics in the Democratic Republic of the Congo, the International Federation of Red Cross and Red Crescent Societies (IFRC) has launched an emergency appeal, calling for 2.2 million Swiss francs to support activities in response to ongoing yellow fever, measles, and cholera outbreaks.

In March, a yellow fever outbreak was declared after 39 cases were reported imported from neighbouring Angola. The cholera outbreak has resulted in close to 6,000 cases and 94 deaths since the beginning of the year, while the measles epidemic has produced at least 749 cases, resulting in 26 deaths.

The Red Cross of the Democratic Republic of Congo has been a key partner of the Congolese government in the fight against recurrent epidemics, most recently deploying volunteers to raise awareness about preventative measures against yellow fever…

NIH [to 23 July 2016]

NIH [to 23 July 2016]

July 18, 2016
HIV therapy for breastfeeding mothers can virtually eliminate transmission to babies
For HIV-infected mothers whose immune system is in good health, taking a three-drug antiretroviral regimen during breastfeeding essentially eliminates HIV transmission by breast milk to their infants, according to results from a large clinical trial conducted in sub-Saharan Africa and India.

These findings from the ongoing Promoting Maternal and Infant Survival Everywhere (PROMISE) study, funded by the National Institutes of Health, support the World Health Organization (WHO) guidelines introduced in 2015 that recommend lifelong antiretroviral therapy for all pregnant and breastfeeding women living with HIV. PROMISE investigators found that both three-drug maternal antiretroviral therapy and daily infant nevirapine were safe and effective at preventing HIV transmission during breastfeeding. Overall, infant mortality in the study was extremely low, with nearly all babies surviving their first year of life.

“These findings add to the considerable body of evidence confirming the benefits of antiretroviral therapy for every person living with HIV,” said Anthony S. Fauci, M.D., director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID). “Maternal antiretroviral therapy safely minimizes the threat of HIV transmission through breast milk while preserving the health advantages of breastfeeding, as the high infant survival in this study underscores.”…

AIDS 2016 – Durban, South Africa – Vaccines are Needed to Conclusively End HIV/AIDS and TB

AERAS/ IAVI – International AIDS Vaccine Initiative

AIDS 2016 – Durban, South Africa
Session Title: Vaccines are Needed to Conclusively End HIV/AIDS and TB
Monday 18 July, 08:00 – 10:00
Co-Chairs: Jacqueline Shea, Aeras, United States
Mark Feinberg, International AIDS Vaccine Initiative (IAVI), United States
Aeras, International AIDS Vaccine Initiative (IAVI)
The urgency of the highly interrelated TB and HIV/AIDS epidemics has prompted calls for a rapid and robust scale-up of TB and HIV vaccine research efforts and close collaboration between TB and HIV vaccine development programs. Those at risk for TB and HIV need more choices in prevention to circumvent structural, societal and cultural factors that hinder access and adherence. This session will discuss the importance of vaccine development and deployment to conclusively end HIV/AIDS and TB; it will describe the progress already made, as well as the challenges faced, and the potential for enhanced collaboration between TB and HIV vaccine researchers and developers. This session is targeted to researchers, policymakers, healthcare providers, product developers, civil society, and other stakeholders interested in ending the TB and HIV/AIDS epidemics.

Leading South African research centres join forces

Wellcome Trust [to 23 July 2016]

18 July 2016
Leading South African research centres join forces
Two world-famous health research centres in KwaZulu-Natal, South Africa, are joining forces in a bid to tackle HIV, TB and related diseases.
The new organisation, the Africa Health Research Institute (AHRI), is possible because of support from Wellcome and the Howard Hughes Medical Institute (HHMI).

AHRI combines the:
:: Africa Centre for Population Health’s detailed population data from over 100,000 participants
:: KwaZulu-Natal Research Institute for TB-HIV’s world-class facilities, and expertise in basic science and experimental medicine.

AHRI is committed to working towards the elimination of HIV and TB. Researchers want to develop new drugs and vaccines and understand how best to introduce these treatments to reduce infection and improve people’s quality of life. Their ethos is ‘population to laboratory – and back to population’.
The founding of the new institute comes at a critical time. Despite advances in HIV therapy and many declaring that we are nearing ‘the end of AIDS’, HIV and TB remain devastating diseases.

The province of KwaZulu-Natal has the highest HIV burden in South Africa. TB is responsible for more than 14% of deaths in the region. Doctors are also reporting the emergence of drug resistance strains of TB and HIV, which is a clear threat to public health.

Professor Deenan Pillay, Director of the Africa Centre for Population Health, and incoming Director of AHRI, said: “This is the one place in the world where the marrying of disciplines can have maximum impact on new HIV infections and TB transmission.”

AHRI has received a total investment of £51.4 million from Wellcome and HHMI. University College London and the University of KwaZulu-Natal are significant academic partners.
For more information, please read the AHRI press release.

MSF/Médecins Sans Frontières [to 23 July 2016]

MSF/Médecins Sans Frontières [to 23 July 2016]

Press release
MSF Report Shows Price of Newer HIV Medicines 18 Times More Expensive Than First-Line Treatment
July 21, 2016
Trade agreements and pressure on India’s ‘pharmacy of the developing world’ pose major threats to access

Press release
International AIDS Conference: MSF Calls for Immediate Implementation of Quality HIV Care in Neglected Communities
July 19, 2016
Durban, South Africa—Global HIV/AIDS leaders at the International AIDS Conference in Durban must develop and implement an action plan to address the critical lack of access to HIV treatment in countries in West and Central Africa where coverage remains below 30 percent, said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) Tuesday.